Travoprost 0.004% With and Without Benzalkonium Chloride: A Comparison of Safety and Efficacy

Ra, Lewis; Gj, Katz; Weiss, Mitchell J.; Ta, Landry; Je, Dickerson; Je, James; Hua, Shan; Ek, Sullivan; Db, Montgomery; Dt, Wells; Mv, Bergamini

doi:10.1097/01.ijg.0000212274.50229.c6

Cited by 112 publications

(87 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…19,22,24 In addition, when comparing travoprost with BAK (Travatan ® ; Alcon Laboratories, Inc., Fort Worth, Texas, USA) to travoprost with sofZia ™ (Travatan Z ® ; Alcon Laboratories, Inc., Fort Worth, Texas, USA), the IOP-lowering effi cacy was found to be identical. 25 Thus, it appears that BAK is not required for either safety or effi cacy of travoprost as an ocular hypotensive agent.…”

Section: Discussionmentioning

confidence: 99%

Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients

Horsley

Kahook²

2009

OPTH

View full text Add to dashboard Cite

Purpose: To quantify changes in tear break-up time (TBUT), corneal staining and ocular surface disease index (OSDI) in glaucoma patients after switching therapy from latanoprost with 0.02% benzalkonium chloride (BAK) to travoprost with sofZia ™ . Methods: Prospective consecutive case series evaluating patients before and 8 weeks after switching from latanoprost with BAK to travoprost with sofZia ™ in patients with baseline TBUT less than 6 seconds.Results: Forty eyes of 20 consecutive patients using latanoprost with BAK were switched to travoprost with sofZia ™ . Mean TBUT prior to starting travoprost was 2.02 ± 0.71 seconds and increased to 6.34 ± 1.31 seconds 8 weeks after the switch (p Ͻ 0.001). Mean inferior corneal staining scores decreased from 2.40 ± 0.87 to 1.38 ± 0.59 (p Ͻ 0.001). Mean OSDI scores decreased from 26.31 ± 8.25 to 16.56 ± 6.19 (p Ͻ 0.001). Discussion: This report focuses on the status of the ocular surface, as documented by TBUT, corneal staining and OSDI, in patients switched from latanoprost with BAK to travoprost without BAK. The switch resulted in a statistically signifi cant increase in TBUT and decreases in corneal staining and OSDI in patients with low baseline TBUT values. Conclusion: BAK, a common preservative for glaucoma drops, may increase OSD by disrupting the tear fi lm and increasing conjunctival infl ammation. In this study, a change from a BAK-preserved prostaglandin analog (PGA) to a non-BAK-preserved PGA resulted in a measurable improvement of TBUT, corneal staining and OSDI. Further studies are needed to better understand the impact of BAK-preserved medications on the ocular surface.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients

Horsley

Kahook²

2009

OPTH

View full text Add to dashboard Cite

show abstract

“…[41][42][43] In particular, Hamacher et al 41 in a pharmacodynamics analysis did not find statistically significant differences between BAK-free and BAKcontaining formulations in the incidence of ocular adverse events comparing preservative-free tafluprost with tafluprost containing 0.01% BAK. Also, in the work of Gross et al 42 , travoprost BAK free and travoprost preserved with BAK showed no differences in the safety and Lewis et al 43 have demonstrated no differences in the incidence of side ocular effects, comparing travoprost 0.004% containing 0.015% BAK with travoprost 0.004% BAK free.…”

Section: Discussionmentioning

confidence: 99%

Bimatoprost 0.01% vs bimatoprost 0.03%: a 12-month prospective trial of clinical and in vivo confocal microscopy in glaucoma patients

Figus

Nardi

Piaggi

et al. 2014

Eye

View full text Add to dashboard Cite

Results Global clinical score (the sum of pruritus, stinging/burning, blurred vision, sticky eye sensation, eye dryness sensation, and foreign body sensation) significantly decreased in the bimatoprost 0.01% group from baseline 4.7±3.8 to 2.9±2.3 (Po0.001) and 2.5±2.0 (Po0.001) at 6-month and 12-month follow-ups, respectively. Comparison between groups showed differences at both follow-up visits (P ¼ 0.003 and Po0.001, respectively). In vivo confocal microscopy revealed a significant increase in goblet cell density in the bimatoprost 0.01% group compared with the bimatoprost 0.03% group (Po0.001 at both follow-up visits). All functional parameters and conjunctival hyperemia improved in the bimatoprost 0.01% group at each follow-up visit (Po0.05) and in comparison with bimatoprost 0.03% (Po0.05). ConclusionThe results of this trial suggest that bimatoprost 0.01% eye drops seem to decrease the ocular discomfort with respect to bimatoprost 0.03% eye drops.

show abstract

“…Further analysis was performed to determine which of the five medicated gels was most suitable for ophthalmic delivery of cysteamine. Benzalkonium chloride is the most widely used preservative in ophthalmic preparations (Lewis, et al 2007;Marple, et al 2004). …”

Section: Resultsmentioning

confidence: 99%

Preformulation of cysteamine gels for treatment of the ophthalmic complications in cystinosis

McKenzie

Kay

Matthews

et al. 2016

International Journal of Pharmaceutics

View full text Add to dashboard Cite

Travoprost 0.004% With and Without Benzalkonium Chloride: A Comparison of Safety and Efficacy

Abstract: Travoprost 0.004% without BAC is equivalent to travoprost 0.004% with BAC in both safety and efficacy.

Cited by 112 publications

References 20 publications

Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients

Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients

Bimatoprost 0.01% vs bimatoprost 0.03%: a 12-month prospective trial of clinical and in vivo confocal microscopy in glaucoma patients

Preformulation of cysteamine gels for treatment of the ophthalmic complications in cystinosis

Contact Info

Product

Resources

About